We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat
Read MoreHide Full Article
Deciphera Pharmaceuticals, Inc. reported second-quarter 2021 loss of $1.21 per share, wider than the Zacks Consensus Estimate of a loss of $1.15 and the year-ago quarter’s loss of $1.20. The loss was attributed to increased research and development expenses incurred during the quarter.
Total net revenues were $23.6 million in the quarter, which beat the Zacks Consensus Estimate of $22.3 million. Revenues were up 232% year over year.
Shares of the company have lost 48.3% in the year so far compared with the industry’s decline of 1.1%.
Image Source: Zacks Investment Research
Quarter in Detail
In May 2020, Qinlock was approved by the FDA for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Apart from Qinlock, there are no other marketable drugs in the company’s pipeline. Total revenues comprised net product revenues and collaboration revenues. Net product revenues were $22 million, inclusive of $20.7 million in U.S. sales and $1.3 million in ex-U.S. sales.
Collaboration revenues of $1.5 million comprised commercial supply and royalty revenues under the company’s license agreement with Zai Lab. In March 2021, the company collaborated with Zai Labs to commercially launch Qinlock in China for the treatment of adult patients with fourth-line GIST.
Research and development expenses were $60 million, up 30% year over year. The increase was attributed to personnel and preclinical costs as well as increased clinical costs on ongoing phase I/II study on vimseltinib.
Selling, general and administrative expenses were $32.8 million, up from $29.9 million in the year-ago quarter due to personnel costs as well as external spend related to professional fees, including those associated with establishing a targeted commercial infrastructure in key European markets to support a potential launch of Qinlock in Europe, if approved.
Deciphera had cash, cash equivalents and investments worth $451 million as of Jun 30, 2021, down from $502.2 million as of Mar 31, 2021.
Pipeline Updates
Deciphera plans to initiate a phase I/IIb study of Qinlock in combination with Mektovi (binimetinib), in post-imatinib GIST patients in the fourth quarter.
Top-line results for the INTRIGUE phase III study on Qinlock are expected in the fourth quarter of 2021.The company anticipates a potential approval in Europe for Qinlock in the fourth quarter.
In June 2021, Deciphera initiated phase I study to evaluate its investigational ULK kinase inhibitor, DCC-3116, to treat patients with advanced/metastatic tumors driven by mutations in RAS/RAF genes. The study is investigating DCC-3116 as a single agent and also in combination with Mekinist (trametinib), an FDA-approved MEK inhibitor.
The company plans to finalize pivotal development plans in second-half 2021 for vimseltinib and rebastinib to treat tenosynovial giant cell tumor (TGCT) and solid tumors, respectively.
Our Take
The initial uptake of Qinlock has been encouraging and the company is working to expand access to this medicine globally. The successful results of the INTRIGUE study (expected later in the year) will broaden the targeted market further (larger, second-line patient population).
Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.69 in the past 30 days. The same for 2022 has moved north from $2.56 to $2.94 over the same period. The stock has rallied 30% in the year so far.
Vanda’s earnings per share estimates for 2021 have increased from $0.62 to $0.67 in the past 30 days. The same for 2022 has been revised upward from $0.80 to $1.01 over the same period. The stock has risen 28.8% in the year so far.
Vertex’s earnings per share estimates for 2021 have been raised from $11.20 to $12.21 in the past 30 days. The same for 2022 has been revised upward from $12.25 to $13.00 over the same period.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat
Deciphera Pharmaceuticals, Inc. reported second-quarter 2021 loss of $1.21 per share, wider than the Zacks Consensus Estimate of a loss of $1.15 and the year-ago quarter’s loss of $1.20. The loss was attributed to increased research and development expenses incurred during the quarter.
Total net revenues were $23.6 million in the quarter, which beat the Zacks Consensus Estimate of $22.3 million. Revenues were up 232% year over year.
Shares of the company have lost 48.3% in the year so far compared with the industry’s decline of 1.1%.
Image Source: Zacks Investment Research
Quarter in Detail
In May 2020, Qinlock was approved by the FDA for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Apart from Qinlock, there are no other marketable drugs in the company’s pipeline. Total revenues comprised net product revenues and collaboration revenues. Net product revenues were $22 million, inclusive of $20.7 million in U.S. sales and $1.3 million in ex-U.S. sales.
Collaboration revenues of $1.5 million comprised commercial supply and royalty revenues under the company’s license agreement with Zai Lab. In March 2021, the company collaborated with Zai Labs to commercially launch Qinlock in China for the treatment of adult patients with fourth-line GIST.
Research and development expenses were $60 million, up 30% year over year. The increase was attributed to personnel and preclinical costs as well as increased clinical costs on ongoing phase I/II study on vimseltinib.
Selling, general and administrative expenses were $32.8 million, up from $29.9 million in the year-ago quarter due to personnel costs as well as external spend related to professional fees, including those associated with establishing a targeted commercial infrastructure in key European markets to support a potential launch of Qinlock in Europe, if approved.
Deciphera had cash, cash equivalents and investments worth $451 million as of Jun 30, 2021, down from $502.2 million as of Mar 31, 2021.
Pipeline Updates
Deciphera plans to initiate a phase I/IIb study of Qinlock in combination with Mektovi (binimetinib), in post-imatinib GIST patients in the fourth quarter.
Top-line results for the INTRIGUE phase III study on Qinlock are expected in the fourth quarter of 2021.The company anticipates a potential approval in Europe for Qinlock in the fourth quarter.
In June 2021, Deciphera initiated phase I study to evaluate its investigational ULK kinase inhibitor, DCC-3116, to treat patients with advanced/metastatic tumors driven by mutations in RAS/RAF genes. The study is investigating DCC-3116 as a single agent and also in combination with Mekinist (trametinib), an FDA-approved MEK inhibitor.
The company plans to finalize pivotal development plans in second-half 2021 for vimseltinib and rebastinib to treat tenosynovial giant cell tumor (TGCT) and solid tumors, respectively.
Our Take
The initial uptake of Qinlock has been encouraging and the company is working to expand access to this medicine globally. The successful results of the INTRIGUE study (expected later in the year) will broaden the targeted market further (larger, second-line patient population).
Deciphera Pharmaceuticals, Inc. Price
Deciphera Pharmaceuticals, Inc. price | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Deciphera currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks worth considering in the same sector are Repligen (RGEN - Free Report) , Vanda Pharmaceuticals (VNDA - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) , all of which currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.69 in the past 30 days. The same for 2022 has moved north from $2.56 to $2.94 over the same period. The stock has rallied 30% in the year so far.
Vanda’s earnings per share estimates for 2021 have increased from $0.62 to $0.67 in the past 30 days. The same for 2022 has been revised upward from $0.80 to $1.01 over the same period. The stock has risen 28.8% in the year so far.
Vertex’s earnings per share estimates for 2021 have been raised from $11.20 to $12.21 in the past 30 days. The same for 2022 has been revised upward from $12.25 to $13.00 over the same period.